MetaVia

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MetaVia and other ETFs, options, and stocks.

About MTVA

MetaVia, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. 

CEO
Hyung-Heon Kim
CEOHyung-Heon Kim
Employees
8
Employees8
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2014
Founded2014
Employees
8
Employees8

MTVA Key Statistics

Market cap
9.79M
Market cap9.79M
Price-Earnings ratio
-0.31
Price-Earnings ratio-0.31
Dividend yield
Dividend yield
Average volume
2.86M
Average volume2.86M
High today
$1.95
High today$1.95
Low today
$1.66
Low today$1.66
Open price
$1.79
Open price$1.79
Volume
918.60K
Volume918.60K
52 Week high
$19.03
52 Week high$19.03
52 Week low
$0.9661
52 Week low$0.9661

Stock Snapshot

MetaVia(MTVA) stock is priced at $1.83, giving the company a market capitalization of 9.79M. It carries a P/E multiple of -0.31.

During the trading session on 2026-06-09, MetaVia(MTVA) shares reached a daily high of $1.95 and a low of $1.66. At a current price of $1.83, the stock is +10.2% higher than the low and still -6.4% under the high.

Trading volume for MetaVia(MTVA) stock has reached 918.6K, versus its average volume of 2.86M.

The stock's 52-week range extends from a low of $0.97 to a high of $19.03.

The stock's 52-week range extends from a low of $0.97 to a high of $19.03.

MTVA News

TipRanks 1d
MetaVia Shareholders Approve Equity Plan and Reverse Split

MetaVia ( (MTVA) ) has issued an update. At its virtual annual meeting of stockholders held on June 8, 2026, MetaVia Inc. secured shareholder approval for the...

TipRanks 2d
MetaVia highlights obesity and metabolic pipeline advancements

Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-co...

TipRanks 2d
MetaVia presents data at ADA supporting DA-1726, vanoglipel

MetaVia (MTVA) announced the presentation of new late-breaking data highlighting its obesity and metabolic disease portfolio at the American Diabetes Associatio...

More MTVA News

Investing.com 2d
MetaVia reports obesity drug data at diabetes conference - Investing.com

...

MetaVia reports obesity drug data at diabetes conference - Investing.com

People also own

Based on the portfolios of people who own MTVA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.